InvestorsHub Logo
Followers 5213
Posts 24013
Boards Moderated 5
Alias Born 09/20/2000

Re: C.R.T post# 44709

Tuesday, 10/10/2017 3:53:16 PM

Tuesday, October 10, 2017 3:53:16 PM

Post# of 94101
TXTM*Cannabis Biosciences & GW Pharmaceuticals Comparison...

Thanks for posting this. First, I think investors need to know that the government of South Africa (SA) submitted a Bill to become part of law that was first published in Mar 2017. The Bill clearly outlines what you have to do to pursue obtaining a Marijuana License in South Africa (SA). The Bill allows for the government of South Africa (SA) to have the authority to approve who's authorized to grow cannabis and conduct cannabis research for the purpose of medicines. The post below explains the importance of Oct 13, 2017 and how TXTM is positioned to obtain approval of the marijuana License they are seeking for the country of South Africa (SA) to grow cannabis and conduct cannabis research for the purpose of medicines:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134835060

TXTM has brought Plandai Biotechnology SA and Cannabis Bioscience, Inc. under them as wholly-owned subsidiaries. Both will be instrumental in the growth of TXTM as Cannabis Bioscience, Inc. has been created after the GW Pharmaceuticals business model.

Now all should go to the TXTM video below and skip to 2:30 and listen to the TXTM CEO who states that... the Marijuana License that we are going after - there are only a few issued around the world and the principal player that hold this license is GW Pharmaceuticals. As indicated within the post below,

What TXTM is getting ready to obtain approval for is absolutely huge. For inquiring minds... GW Pharmaceuticals trades on the NASDAQ at $110.00+ per share and is a $2.8 Billion company:
https://finance.yahoo.com/quote/GWPH/

https://www.gwpharm.com/



v/r
Sterling



Exit Strategy & Etiquette Thoughts for a Stock
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128822531